Meng Xufeng, Zheng Zhi, Yang Li, Yang Chen, Li Xiaoli, Hao Yunfei
First Clinical Medicine College, College of Integrated Traditional Chinese and Western Medicine, Gansu University of Traditional Chinese Medicine, Lanzhou, China.
Key Laboratory of Cerebrovascular Diseases of Gansu Province, Cerebrovascular Disease Center, Gansu Provincial People's Hospital, Lanzhou, China.
Front Neurosci. 2025 Aug 18;19:1649533. doi: 10.3389/fnins.2025.1649533. eCollection 2025.
Cerebral ischemia-reperfusion injury (CI/RI) is a critical event causing secondary neurological deterioration following vascular recanalization in patients with ischemic stroke (IS), involving multiple interrelated pathological processes that synergistically aggravate brain injury. However, the underlying mechanisms remain incompletely elucidated, necessitating systematic investigation. This review systematically elucidates the dynamic pathological mechanisms underlying CI/RI during ischemic and reperfusion phases. Hypoxia-induced mitochondrial energy failure and TLR4/NF-κB-mediated inflammation predominate in the ischemic phase, while reperfusion triggers a reactive oxygen species (ROS) burst, amplifying oxidative stress (OS). These interconnected cascades form a self-perpetuating pathological loop. Targeting these pathways, therapies such as the TLR4 antagonist ApTOLL, the iron chelator deferoxamine, and the free radical scavenger Edaravone have shown promise. Nevertheless, significant challenges persist, including single-target limitations, poor delivery efficiency across the blood-brain barrier, and insufficient mechanistic insights. By integrating dynamic mechanisms and corresponding therapeutic strategies, this review summarizes recent advances in understanding the core pathological mechanisms and targeted interventions for CI/RI, discusses the current status and future prospects of these mechanisms and therapies, and aims to provide a systematic framework for mechanistic insights into CI/RI and a theoretical foundation for its precision treatment.
脑缺血再灌注损伤(CI/RI)是缺血性脑卒中(IS)患者血管再通后导致继发性神经功能恶化的关键事件,涉及多个相互关联的病理过程,这些过程协同加重脑损伤。然而,其潜在机制仍未完全阐明,需要进行系统研究。本综述系统地阐明了缺血和再灌注阶段CI/RI的动态病理机制。缺氧诱导的线粒体能量衰竭和TLR4/NF-κB介导的炎症在缺血阶段占主导地位,而再灌注触发活性氧(ROS)爆发,放大氧化应激(OS)。这些相互关联的级联反应形成了一个自我延续的病理循环。针对这些途径,如TLR4拮抗剂ApTOLL、铁螯合剂去铁胺和自由基清除剂依达拉奉等疗法已显示出前景。然而,重大挑战依然存在,包括单靶点局限性、血脑屏障递送效率低下以及机制认识不足。通过整合动态机制和相应的治疗策略,本综述总结了CI/RI核心病理机制和靶向干预方面的最新进展,讨论了这些机制和疗法的现状与未来前景,旨在为CI/RI的机制研究提供系统框架,并为其精准治疗提供理论基础。